ArticleFrontiers in medicine2026
Sustained intraocular pressure lowering from suprachoroidal injection of a latanoprost lipid nanoparticle delivery system in the rabbit.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current treatments for glaucoma to lower intraocular pressure (IOP) are dependent on patient adherence and bioavailability after bypassing ocular barriers. Our study investigated the safety and efficacy of a liposomal nanocarrier for sustained release of latanoprost injected into the suprachoroidal space in the rabbit eye. Methods: Dutch-Belt rabbits were injected with a single dose of 150 μL of 2 mg/mL of liposomal latanoprost formulation into the suprachoroidal space. The eyes were clinically monitored for adverse events and the IOP recorded. Results: IOP reduced from baseline to 8 h post liposomal latanoprost injection by 28% (5.1 ± 2.12 mmHg), reaching a maximum of 40% (7.2 ± 1.9 mmHg) at Day 5. Low IOP was sustained until Day 56 returning to baseline at Day 90. Safety assessment of the eyes showed no adverse events and good tolerability of the drug. Conclusion: A single dose of liposomal latanoprost into the suprachoroidal space can lower the IOP for up to 56 days making it a promising therapeutic agent for sustained delivery drugs to the suprachoroidal space.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.